Endotoxin pp 665-676 | Cite as

Immunotherapy with Bacterial Endotoxins

  • J. A. Rudbach
  • J. L. Cantrell
  • J. T. Ulrich
  • M. S. Mitchell
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 256)


Since the recognition that humoral and cellular elements of the body provide protection and are responsible for natural recovery from various diseases (32), attempts have been made to enhance these mechanisms. At first, vaccines specifically targeted to the agent of the disease were employed (18). Subsequently, nonspecific stimulants were tested for their ability to protect man and other animals from infectious diseases and to provide therapeutic benefit in diseased hosts (24, 32). Ultimately, it was only natural that the nonspecific stimulants would be tested for their ability to enhance, or adjuvantize the specific resistance induced by vaccines.


Bacterial Endotoxin Brucella Abortus Monophosphoryl Lipid Secondary Antibody Response Cell Wall Skeleton 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baker, P. J., Hiernaux, J. R., Fauntleroy, M. B., Prescott, B., Cantrell, J. L., and Rudbach, J. A., 1988, Inactivation of suppressor T cell activity by nontoxic monophosphoryl lipid A (MPL). Infect. Immun. 56: 1076.Google Scholar
  2. 2.
    Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., Cantrell, J. L., and Zighelboim, J., 1985, Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Cancer Res. 45: 4215.PubMedGoogle Scholar
  3. 3.
    Cantrell, J. L., and Finn, D. J., 1988, Role of novel adjuvants in specific active immunotherapy, in: “Immunity to Cancer II,” M. S. Mitchell, ed. Alan R. Liss, New York.Google Scholar
  4. 4.
    Chase, J. J., Kubey, W., Dulek, M. H., Holmes, C. J., Salit, M. G., Pearson, III, F. C., and Ribi, E., 1986, Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect. Immun. 53: 711.Google Scholar
  5. 5.
    Freund, J., 1956, The mode of action of immunologic adjuvants, in: “Advances in Tuberculosis Research,” vol 7, H. Birkhauser and H. Bloch, eds. S. Krager, New York.Google Scholar
  6. 6.
    Greisman, S. E., Wagner, Jr., H. N., Iio, M., Hornick, R. B., Carozza, Jr., F. M., and Woodward, T. E., 1964, Mechanisms of endotoxin tolerance in man, in: “Bacterial Endotoxins,” M. Landy and W. Braun, eds. Rutgers University Press, New Brunswick, N.J.Google Scholar
  7. 7.
    Johnson, A. G., Gaines, S., and Landy, M., 1956, Studies on the 0-antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J. Exptl. Med. 103: 225.Google Scholar
  8. 8.
    Kasai, N., and Nowotny, A., 1967, Endotoxic glycolipid from a heptoseless mutant of Salmonella minnesota. J. Bacteriol. 94: 1824.PubMedGoogle Scholar
  9. 9.
    Landy, M. and Pillemer, L., 1956, Increased resistance to infection and accompanying alterations in properdin levels following administration of bacterial lipopolysaccharides. J. Exptl. Med. 104: 383.Google Scholar
  10. 10.
    Leong, D. L. Y. and Rudbach, J. A., 1971, Antigenic competition between an endotoxic adjuvant and a protein antigen. Infect. Immun. 3: 308.Google Scholar
  11. 11.
    McLaughlin, C. A., Cantrell, J. L., Ribi, E., and Goldberg, E., 1978, Intratumor chemoimmunotherapy with mitomycin C and components from mycobacteria in regression of line 10 tumors in guinea pigs. Cancer Res. 38: 1311.PubMedGoogle Scholar
  12. 12.
    Milner, K. C., Rudbach, J. A., and Ribi, E., 1971, General Characteristics, in: “Microbial Toxins,” vol 4, G. Weinbaum, S. Kadis, and S. J. Ajl, eds. Academic Press, New York.Google Scholar
  13. 13.
    Mitchell, M. S., 1988, Active specific immunotherapy in the treatment of human cancer, in: “Immunity to Cancer II,” M. S. Mitchell, ed. Alan R. Liss, New York.Google Scholar
  14. 14.
    Moore, F. D., 1960, Relevance of experimental shock studies to clinical shock problems, in: “Recent Progress and Present Problems in the Field of Shock,” S. F. Se Tey, and J. R. Weisiger, eds. Fed. Amer. Soc. for Exper. Biol., Wash. D.C.Google Scholar
  15. 15.
    Morrison, D. C. and Ryan, J. L., 1979, Bacterial endotoxins and host immune responses, in: “Advances in Immunology,” vol. 28, F. J. Dixon and H. G. Kunkel, eds. Academic Press, NY.Google Scholar
  16. 16.
    Munoz, J., 1964. Effect of bacteria and bacterial products on antibody response, in: “Advances in Immunology,” vol 4, F. J. Dixon, Jr., and J. H. Humphrey. eds. Academic Press, New York.Google Scholar
  17. 17.
    Nauts, A. C., Swift, W. E., and Coley, B. L., 1946, Treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M. D., reviewed in light of modern research. Cancer Res. 6: 205.Google Scholar
  18. 18.
    Parish, H. J., 1965, “A History of Immunization,” E. S. Livingstone, Ltd., London.Google Scholar
  19. 19.
    Qureshi, N., Mascagni, P., Ribi, E., and Takayama, K., 1985, Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R 595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem. 260: 5271.Google Scholar
  20. 20.
    Qureshi, N., Takayama, K., and Ribi, E., 1982, Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257: 11808.Google Scholar
  21. 21.
    Ribi, E., Amano, K., Cantrell, J., Schwartzman, S., Parker, R., and Takayama, K., 1982, Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother. 12: 91.Google Scholar
  22. 22.
    Ribi, E., Cantrell, J., Feldner, T., Myers, K., and Peterson, J., 1986, Biological activities of monophosphoryl lipid A, in: “Microbiology 1986,” L. Levie, P. F. Bonventre, J. A. Morello, S. D. Silver, and H. C. Wu, eds. Amer. Soc. for Microbiol., Wash. D.C.Google Scholar
  23. 23.
    Ribi, E. E., Cantrell, J., Schwartzman, S., and Parker, R., 1981, BCG cell wall skeleton, P3, MDP and other microbial components - structure activity studies in animal models, in: “Augmenting Agents in Cancer Therapy,” E. M. Hersh, M. A. Chirigos, and M. J. Mastrangelo, eds. Raven Press, New York.Google Scholar
  24. 24.
    Rowley, D., 1964. Endotoxin-induced changes in susceptibility to infections, in: “Bacterial Endotoxins”, M. Landy and W. Braun, eds. Rutgers University Press New Brunswick, N.J.Google Scholar
  25. 25.
    Rudbach, J. A., 1971, Molecular immunogenicity of bacterial lipopolysaccharide antigens: establishing a quantitative system. J. Immunol. 4: 993.Google Scholar
  26. 26.
    Rudbach, J. A., Cantrell, J. L., and Ulrich, J. T., 1989, Molecularly engineered microbial immunostimulators, in: “Technological Advances in Vaccine Development,” Alan R. Liss, Inc., New York.Google Scholar
  27. 27.
    Simmons, R. L., and Rios, A., 1972, Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase II. Intratumor injections of neuraminidase. Surgery 71: 556.Google Scholar
  28. 28.
    Takayama, K., Qureshi, N., Ribi, E., and Cantrell, J. L., 1984, Separation and characterization of toxic and nontoxic forms of lipid A. Rev. Infect. Dis. 6: 439.Google Scholar
  29. 29.
    Ulrich. J. T., Masihi, K. N., and Lange, W., 1988, Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL), in: “Advances in the Biosciences” vol 68. K. N. Masihi and W. Lange, eds. Pergamon Press New York.Google Scholar
  30. 30.
    Von Eschen, K. B., and Rudbach, J. A., 1974, Immunological responses of mice to native protoplasmic polysaccharide and lipopolysaccharide. J. Exptl. Med. 140: 1604.Google Scholar
  31. 31.
    Westphal, O., and Luderitz, O., 1954, Chemische Erforschung von Lipopolysacchariden gramnegativer Bakterien. Angew. Chem. 66: 407.Google Scholar
  32. 32.
    Wilson, G. S., and Miles, A. A., 1955, “Topley and Wilson’s Principles of Bacteriology and Immunity,” The Williams & Wilkins Co. Google Scholar
  33. 33.
    Young, L. S., 1985, Gram-negative sepsis, in: “Principles and Practice of Infectious Diseases,” G. L. Mandell, R. G. Douglas, Jr., and J. E. Bennett, eds. John Wiley & Sons, New York.Google Scholar
  34. 34.
    Zbar, B., Bernstein, I. D., Bartlett, G. L., Hanna, Jr.. M. G., and Rapp, H. J., 1972. Immunotherapy of Cancer: Regression of intradermal tumors and prevention of growth of lymph node metastases after injection of living Mycobacterium bovis. J. Natl. Cancer Inst. 49: 119.Google Scholar
  35. 35.
    Zbar, B., Ribi, E., and Rapp, H. J., 1973, An experimental model for immunotherapy of cancer. Natl. Cancer Inst. Monograph 39: 3.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • J. A. Rudbach
    • 1
  • J. L. Cantrell
    • 1
  • J. T. Ulrich
    • 1
  • M. S. Mitchell
    • 2
  1. 1.Ribi ImmunoChem Research, Inc.HamiltonUSA
  2. 2.Departments of Medicine and MicrobiologyUniversity of Southern California School of MedicineLos AngelesUSA

Personalised recommendations